DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for retinal degeneration — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRetinal degeneration maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for retinal degeneration is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 2 (NR3C2) — NR3C2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2,2-difluoro-3-hydroxypropyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4PF3 · 1.1 Å · ligand 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one (HFN). Experimental structure, not a prediction.
What the evidence adds up to
Inherited retinal degenerative diseases are a genetically and phenotypically heterogeneous group of disorders that affect photoreceptor function and are among the leading causes of blindness. Research into the molecular and genetic basis of these diseases has identified several non-syndromic retinitis pigmentosa genes, and defects in genes expressed in the retinal pigment epithelium can also cause degeneration. The proximity of photoreceptors and RPE cells means that delivering normal copies of defective genes or genes that enhance cell survival to these tissues may arrest the degenerative process and preserve vision.
The first FDA- and EMA-approved gene therapy for a genetic disease, voretigene neparvovec-rzyl (Luxturna), has been developed for retinal degeneration. Gene therapy trials are now taking place across multiple continents and countries, using several different vectors and routes of administration, with interventional studies reporting promising results. Other emerging therapeutic approaches include stem cell therapy, optogenetics, and retinal prostheses, the last of which has received regulatory approval for artificial replacement of dying photoreceptor cells.
Precise retinal imaging and testing of visual function are facilitating more efficient clinical trial design. In individual patients, disease stage determines whether the strategy should be photoreceptor cell rescue to delay or arrest vision loss, or retinal replacement for vision restoration. The abstracts do not provide concrete numbers for survival, response rates, or sample sizes from any completed trials.
What is still missing are large-scale, long-term trial data comparing these approaches head-to-head, validated biomarkers for patient stratification by disease stage and genotype, and the funding to move beyond early-phase studies into definitive registrational trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Science Translational Medicine · 2016 · 222 citations
Emerging therapies for inherited retinal degeneration
AbstractInherited retinal degenerative diseases, a genetically and phenotypically heterogeneous group of disorders, affect the function of photoreceptor cells and are among the leading causes of blindness. Recent advances in molecular genetics and cell biology are elucidating the pathophysiological mechanisms underlying these disorders and are helping to identify new therapeutic approaches, such as gene therapy, stem cell therapy, and optogenetics. Several of these approaches have entered the clinical phase of development. Artificial replacement of dying photoreceptor cells using retinal prostheses has received regulatory approval. Precise retinal imaging and testing of visual function are facilitating more efficient clinical trial design. In individual patients, disease stage will determine whether the therapeutic strategy should comprise photoreceptor cell rescue to delay or arrest vision loss or retinal replacement for vision restoration.
British Journal of Ophthalmology · 1997 · 33 citations · open access
Gene therapy for inherited retinal degeneration
AbstractResearch into the molecular and genetic basis of disease is continually expanding and improving the prospects for rational treatments. Of these, gene therapy (here defined as the introduction of genetic material into human cells) may ultimately oVer the greatest scope. Of the inherited forms of retinal degeneration, retinitis pigmentosa (RP) is the best characterised (see Bird 2 for review). Seven diVerent non-syndromic RP genes have been identified to date, five of which However, photoreceptors and retinal pigment epithelial (RPE) cells are in close proximity and are interdependent. Defects in genes expressed in the RPE may also result in retinal degeneration. Delivery to these tissues of either normal copies of the defective genes or genes which enhance cell survival may arrest the degenerative process and thus preserve vision.
Cold Spring Harbor Perspectives in Medicine · 2022 · 15 citations · open access
Overview of Retinal Gene Therapy: Current Status and Future Challenges
AbstractThe success of the first Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved gene therapy for genetic disease, voretigene neparovovec-rzyl, (Luxturna) has helped pave the way for development of retinal gene therapies to target other genetic and acquired forms of blindness. Gene therapy trials are now taking place in multiple continents and numerous countries, they use several different gene transfer reagents ("vectors"), studies have used several different routes of administration, and different strategies are being tested in interventional studies with promising results. The future has never been brighter for individuals with retinal degeneration. Here and in the literature cited below, we summarize the state-of-the-art of retinal gene therapy and consider some of the questions and challenges that lie ahead.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
